5.49
price up icon1.29%   0.07
after-market After Hours: 5.53 0.04 +0.73%
loading
Altimmune Inc stock is traded at $5.49, with a volume of 4.18M. It is up +1.29% in the last 24 hours and down -4.85% over the past month. Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
See More
Previous Close:
$5.42
Open:
$5.39
24h Volume:
4.18M
Relative Volume:
1.67
Market Cap:
$445.29M
Revenue:
$409.00K
Net Income/Loss:
$-101.35M
P/E Ratio:
-3.3476
EPS:
-1.64
Net Cash Flow:
$-71.49M
1W Performance:
+0.00%
1M Performance:
-4.85%
6M Performance:
-44.26%
1Y Performance:
-25.61%
1-Day Range:
Value
$5.335
$5.57
1-Week Range:
Value
$5.15
$5.74
52-Week Range:
Value
$3.553
$11.16

Altimmune Inc Stock (ALT) Company Profile

Name
Name
Altimmune Inc
Name
Phone
(240) 654-1450
Name
Address
910 CLOPPER ROAD, GAITHERSBURG, MD
Name
Employee
59
Name
Twitter
Name
Next Earnings Date
2024-11-05
Name
Latest SEC Filings
Name
ALT's Discussions on Twitter

Compare ALT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ALT
Altimmune Inc
5.49 445.28M 409.00K -101.35M -71.49M -1.64
Biotechnology icon
ONC
Beone Medicines Ltd Adr
258.27 26.01B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.85 114.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.3499 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
83.98 6.29B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
484.93 63.90B 14.09B 4.50B 2.96B 39.28

Altimmune Inc Stock (ALT) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-28-25 Initiated William Blair Mkt Perform
Jan-08-25 Initiated Stifel Buy
Nov-12-24 Initiated UBS Buy
Apr-29-24 Downgrade Guggenheim Buy → Neutral
Jan-24-24 Initiated Goldman Neutral
Mar-22-23 Downgrade Goldman Buy → Neutral
Dec-01-22 Initiated Goldman Buy
Dec-29-21 Resumed Jefferies Buy
Jun-02-21 Initiated H.C. Wainwright Buy
Feb-11-21 Initiated Guggenheim Buy
Dec-14-20 Initiated Jefferies Buy
Nov-12-20 Reiterated B. Riley Securities Buy
Sep-25-20 Initiated B. Riley FBR Buy
Aug-14-20 Initiated Evercore ISI Outperform
Jul-31-20 Initiated Piper Sandler Overweight
Jul-28-20 Initiated JMP Securities Mkt Outperform
Feb-24-20 Resumed ROTH Capital Buy
Jul-19-19 Initiated ROTH Capital Buy
Oct-09-17 Initiated Piper Jaffray Overweight
View All

Altimmune Inc Stock (ALT) Latest News

pulisher
Jun 02, 2025

Stifel analysts reaffirm Altimmune stock rating with $18 price target By Investing.com - Investing.com South Africa

Jun 02, 2025
pulisher
Jun 02, 2025

Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential - Seeking Alpha

Jun 02, 2025
pulisher
Jun 02, 2025

Stifel analysts reaffirm Altimmune stock rating with $18 price target - Investing.com

Jun 02, 2025
pulisher
May 31, 2025

Investors who lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - ACCESS Newswire

May 31, 2025
pulisher
May 29, 2025

Altimmune: Upcoming MASH Data Could Be High Impact For Business Development Activity (NASDAQ:ALT) - Seeking Alpha

May 29, 2025
pulisher
May 28, 2025

Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook By Investing.com - Investing.com India

May 28, 2025
pulisher
May 28, 2025

Altimmune’s SWOT analysis: pemvidutide potential drives stock outlook - Investing.com

May 28, 2025
pulisher
May 22, 2025

ALT Hosts Virtual Meeting to Discuss Strategic Developments | ALT Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Northern Trust Corp - Defense World

May 22, 2025
pulisher
May 21, 2025

Could Altimmune, Inc. (ALT): Analysts See 288% Upside Potential - MSN

May 21, 2025
pulisher
May 21, 2025

How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN

May 21, 2025
pulisher
May 21, 2025

Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - AOL.com

May 21, 2025
pulisher
May 20, 2025

Altimmune (ALT) Stock Rises Amid Clinical Trial Progress: What's Going On? - Benzinga

May 20, 2025
pulisher
May 19, 2025

Altimmune begins phase 2 trial for AUD treatment By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluati - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Altimmune (ALT) Begins Phase 2 Trial for Pemvidutide in Treating Alcohol Use Disorder | ALT Stock News - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder - marketscreener.com

May 19, 2025
pulisher
May 19, 2025

Altimmune begins phase 2 trial for AUD treatment - Investing.com

May 19, 2025
pulisher
May 19, 2025

Altimmune Announces Initiation of RECLAIM Phase 2 Trial Evaluating the Efficacy and Safety of Pemvidutide in Alcohol Use Disorder (AUD) - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Breakthrough AUD Drug Enters Phase 2 Trial: New Hope for 28 Million US Patients With Alcohol Use Disorder - Stock Titan

May 19, 2025
pulisher
May 19, 2025

HC Wainwright Has Strong Forecast for Altimmune Q2 Earnings - Defense World

May 19, 2025
pulisher
May 17, 2025

William Blair Estimates Altimmune’s Q2 Earnings (NASDAQ:ALT) - Defense World

May 17, 2025
pulisher
May 17, 2025

Price T Rowe Associates Inc. MD Acquires 4,158 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World

May 17, 2025
pulisher
May 17, 2025

B. Riley Issues Positive Estimate for Altimmune Earnings - Defense World

May 17, 2025
pulisher
May 16, 2025

(ALT) Proactive Strategies - news.stocktradersdaily.com

May 16, 2025
pulisher
May 16, 2025

Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway - MSN

May 16, 2025
pulisher
May 16, 2025

Baird Financial Group Inc. Takes Position in Altimmune, Inc. (NASDAQ:ALT) - The AM Reporter

May 16, 2025
pulisher
May 16, 2025

Stifel Financial Corp Sells 4,649 Shares of Altimmune, Inc. (NASDAQ:ALT) - Defense World

May 16, 2025
pulisher
May 15, 2025

Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

Voya Investment Management LLC Decreases Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World

May 15, 2025
pulisher
May 15, 2025

Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased - MSN

May 15, 2025
pulisher
May 14, 2025

Piper Sandler maintains Altimmune stock with $25 target - Investing.com Australia

May 14, 2025
pulisher
May 14, 2025

Piper Sandler maintains Altimmune stock with $25 target By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Altimmune to Participate at Two Upcoming Investor Conferences | - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Altimmune to Participate at Two Upcoming Investor Conferences | ALT Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Altimmune to Participate at Two Upcoming Investor Conferences - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Altimmune Sets Double Conference Appearance: HC Wainwright and Jefferies Healthcare Events Coming Up - Stock Titan

May 14, 2025
pulisher
May 14, 2025

Altimmune’s 2025 Q1 Results Highlight Clinical Progress - TipRanks

May 14, 2025
pulisher
May 14, 2025

Raymond James Financial Inc. Invests $88,000 in Altimmune, Inc. (NASDAQ:ALT) - Defense World

May 14, 2025
pulisher
May 14, 2025

Altimmune Inc (ALT) Q1 2025 Earnings Call Highlights: Financial Strength and Strategic Developments - Yahoo Finance

May 14, 2025
pulisher
May 14, 2025

Altimmune (ALT) Q1 Revenue Steady as Pemvidutide Developments Pr - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Earnings call transcript: Altimmune Q1 2025 results show narrower loss By Investing.com - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

Altimmune, Inc. SEC 10-Q Report - TradingView

May 13, 2025
pulisher
May 13, 2025

Altimmune (ALT) Advances NASH Treatment and Secures $100M Credit Facility - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Altimmune, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ALT) - Seeking Alpha

May 13, 2025
pulisher
May 13, 2025

ALTI Reports Strong Q1 Revenue Growth | ALTI Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Axsome’s $570M loan with Blackstone; Altimmune makes its own credit deal - Endpoints News

May 13, 2025
pulisher
May 13, 2025

Earnings call transcript: Altimmune Q1 2025 results show narrower loss - Investing.com Australia

May 13, 2025
pulisher
May 13, 2025

Altimmune (ALT) Sees Modest Pre-Market Rise After Earnings Report | ALT Stock News - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Altimmune Secures Credit Facility of Up to $100 Million From Hercules Capital - marketscreener.com

May 13, 2025

Altimmune Inc Stock (ALT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.16
price up icon 0.00%
$573.50
price down icon 0.54%
$36.08
price up icon 15.90%
$305.31
price up icon 0.51%
$4.75
price up icon 3.70%
$484.93
price down icon 0.60%
Cap:     |  Volume (24h):